Lynx1 Capital Management LP 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Lynx1 Capital Management LP disclosed 23 US equity positions worth $632.7m in its Q1 2026 13F filing. The largest position was STOK at 24.5% of the reported book, followed by GHRS and CGEM.
What did Lynx1 Capital Management LP own in Q1 2026? Top 23 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | STOK STOKE THERAPEUTICS INC | Healthcare | 24.5% | $155.1m | 4,763,673 | – | |
| 2 | GHRS GH RESEARCH PLC | Healthcare | 23.9% | $151.3m | 10,763,288 | – | |
| 3 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 20.1% | $127.4m | 8,963,500 | – | |
| 4 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 14.0% | $88.3m | 2,611,568 | – | |
| 5 | DNLI DENALI THERAPEUTICS INC | Healthcare | 5.7% | $36.1m | 1,880,303 | – | |
| 6 | CCCC C4 THERAPEUTICS INC | Healthcare | 2.9% | $18.4m | 6,998,902 | – | |
| 7 | KRRO KORRO BIO INC | Healthcare | 2.8% | $17.4m | 1,538,296 | – | |
| 8 | TCRX TSCAN THERAPEUTICS INC | 1.3% | $8.1m | 8,019,148 | – | ||
| 9 | XNCR XENCOR INC | Healthcare | 1.0% | $6.5m | 536,398 | – | |
| 10 | DTIL PRECISION BIOSCIENCES INC | 0.9% | $5.4m | 985,113 | – | ||
| 11 | PASG PASSAGE BIO INC | 0.8% | $4.9m | 623,704 | – | ||
| 12 | NEUP NEUPHORIA THERAPEUTICS INC | 0.6% | $3.6m | 875,328 | – | ||
| 13 | TRDA ENTRADA THERAPEUTICS INC | 0.4% | $2.7m | 211,689 | – | ||
| 14 | CGON CG ONCOLOGY INC | Healthcare | 0.3% | $2.1m | 31,591 | – | |
| 15 | IMTX IMMATICS N.V | Healthcare | 0.3% | $2.1m | 216,973 | – | |
| 16 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 0.2% | $1.3m | 119,516 | – | |
| 17 | MNLOUSD VYNE THERAPEUTICS INC | 0.2% | $973.1k | 1,628,700 | – | ||
| 18 | HOWL WEREWOLF THERAPEUTICS INC | 0.1% | $547.7k | 657,786 | – | ||
| 19 | IBIO IBIO INC | 0.0% | $129.3k | 68,076 | – | ||
| 20 | BOLT BOLT BIOTHERAPEUTICS INC | 0.0% | $124.4k | 30,800 | – | ||
| 21 | PROQR THRAPEUTICS N V | 0.0% | $110.9k | 68,486 | – | ||
| 22 | ABSI ABSCI CORPORATION | Healthcare | 0.0% | $63.7k | 21,245 | – | |
| 23 | TRAW TRAWS PHARMA INC | 0.0% | $27.6k | 15,078 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.